PATENT CLAIM ANALYSIS

Application Number: 15755700
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "218000"]

Abstract:
The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period of time, said drug comprising an Rho kinase inhibitor, more specifically, to a therapeutic agent comprising an Rho kinase inhibitor for treating glaucoma or ocular hypertension in a patient suffering from glaucoma or ocular hypertension who has been administered with a therapeutic agent comprising the Rho kinase inhibitor for treating glaucoma or ocular hypertension continuously over a definite period of time and needs a further enhanced ocular hypotensive effect.

Claim (Index 11):
A method for preventing and/or treating glaucoma or ocular hypertension, comprising: continuously administrating an effective amount of an agent comprising a Rho kinase inhibitor for a long period of time to a subject in need thereof.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 2.14286
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11993101', '14235097', '12940375', '11995052', '12921497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7675751745643021
- 35 USC 102 Novelty (BERT): 0.5161868465777409
- Combined Prediction Score: 0.742436341765646
- Mean Citation Score: 287.364206
- Max Citation Score: 300.9799
- Similarity Product: 205.2227370505214

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test